国家基本药物目录与WHO示范目录的差异分析  

Comparative analysis between the national essential medicines list and the WHO 2011 model list

作　　者：王丽洁[1] 徐文娟[1] 陈文[1] 张璐莹[1] 蒋虹丽[1] 

机构地区：[1]复旦大学公共卫生学院,上海200032

出　　处：《中国卫生政策研究》2012年第7期21-25,共5页Chinese Journal of Health Policy

基　　金：卫生部统计信息中心资助课题

摘　　要：目的:通过比较我国国家基本药物目录与WHO2011版示范目录的差异,为我国修订和完善国家基本药物目录提供参考。方法:采用WHO官网公开的WHO1977—2011年基本药物示范目录汇总表录入国家基本药物目录西药,进行矩阵表分析。结果:我国国家基本药物目录构成、药物分类方式和适用对象等基本要素,遴选标准、方法等遴选机制,以及收录药品的品种和类别与WHO2011版示范目录存在差异。两目录对同一治疗组推荐药品有所区别,部分国家基本药物品种已被WHO示范目录删除。结论与建议:通过与WHO示范目录比较,可以发现我国基本药物目录存在一些不足,需要进一步完善目录要素和构成,完善遴选机制,并根据WHO示范目录药品的系统证据对现有基本药物品种进行调整。Objective： The paper aims to comparatively analyze the national essential medicines list （NEML） with the WHO 2011 Model list for NEML revision. Method ： Matching NEML medicines into the spreadsheet of histor- ical master list （1977--2011） available on WHO website. Result： the discrepancies between the two lists include el- ements such as list components, medicines classification and application, selection mechanism with criteria and meth- ods, and the specific kind. Two lists selected different medicines for the same therapeutic group and some of China essential medicines have been deleted by WHO list. Conclusion and suggestion： Through the comparison, the deficit of NEML has been revealed, which could be improved by revision of list elements and components, improvement on selection mechanism, and adjustment of medicines based on the systematic review of evidences WHO provided.

关 键 词：基本药物 国家基本药物目录 WHO示范目录 比较研究 

分 类 号：R951[医药卫生—药学]